Correction: Application and development of Organ-on-a-Chip technology in cancer therapy [0.03%]
纠正：器官芯片技术在癌症治疗中的应用及发展
Ling Xiao Wang,Shu Ling Liu,Ning Wu
Ling Xiao Wang
[This corrects the article DOI: 10.3389/fonc.2025.1643230.]. Keywords: biomedical engineering; cancer therap...
Published Erratum
Frontiers in oncology. 2025 Sep 24:15:1703677. DOI:10.3389/fonc.2025.1703677 2025
Editorial: Immune checkpoints regulatory mechanisms and immunotherapy strategies in gastrointestinal tumors [0.03%]
论著：胃肠肿瘤的免疫检查点调节机制及免疫治疗策略
Qing Xi,Rongxin Zhang
Qing Xi
Therapeutic innovations in triple negative breast cancer: integrating molecular targeting and monoclonal antibody strategies [0.03%]
三阴性乳腺癌的治疗创新：分子靶向和单克隆抗体策略的整合
Prince Ahad Mir,Nishant Kumar,Sukesh K Gupta et al.
Prince Ahad Mir et al.
Triple Negative Breast Cancer (TNBC) is a specific kind of breast cancer that is distinguished by the lack of expression of three specific receptors, namely human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and proges...
Impact of dining out frequency on the risk of colorectal cancer: insights from a large Chinese cohort [0.03%]
饮食外出频率对结直肠癌发病风险的影响：一项中国大型队列研究的启示
Pei Zhang,Wen-Jing Xing,Jing Zhang et al.
Pei Zhang et al.
Introduction: Dining out has been shown to be associated with various negative health outcomes. However, the evidence concerning the relationship between dining out of home and the risk of colon and rectal cancers remains...
Editorial: Head and neck squamous cell carcinoma: navigating the dawn of personalized medicine [0.03%]
编辑部：头颈鳞癌的个体化医疗时代的到来
Luis Abel Quiñones,Ye Guo,Fujun Han
Luis Abel Quiñones
Case Report: Delayed diagnosis of parathyroid carcinoma and two pulmonary recurrences and metastases [0.03%]
个例报告：甲状旁腺癌延迟诊断及肺部两处复发和转移
Wenzhi Tian,Chenchen Hu,Tianmin Cao et al.
Wenzhi Tian et al.
Parathyroid carcinoma (PC) is a rare and aggressive malignancy, characterized by severe hypercalcemia and elevated parathyroid hormone (PTH) levels, making it particularly challenging to diagnose. In this case report, the patient's PC was n...
Clinical characteristics and prognosis of breast cancer patients with ovarian metastases [0.03%]
卵巢转移性乳腺癌患者的临床特征及预后分析
Chunyan Gao,Yan Li,Xiaoping Ma et al.
Chunyan Gao et al.
Objective: This study aims to investigate the clinical characteristics, overall survival (OS), and prognostic factors associated with breast cancer patients who have ovarian metastasis (OM). ...
Correction: Editorial: Current status and recent advances in preclinical models for rare cancers [0.03%]
罕见癌症的临床前模型研究现状及最新进展（编辑部推荐）-correction
Ewa Krawczyk,Luciane R Cavalli,Joanna Kitlinska
Ewa Krawczyk
[This corrects the article DOI: 10.3389/fonc.2025.1676020.]. Keywords: cancer models; in vitro cancer models...
Published Erratum
Frontiers in oncology. 2025 Sep 23:15:1697286. DOI:10.3389/fonc.2025.1697286 2025
Mechanistic studies of miR-582-3p targeting of PTPRCAP affecting lung adenocarcinoma via the Wnt/β-catenin pathway [0.03%]
miR-582-3p通过Wnt/β-catenin信号通路靶向PTPRCAP影响肺腺癌的机制研究
Yuting Yang,Song Zhao,Xiaoli Han et al.
Yuting Yang et al.
Objective: To investigate the regulatory mechanism by which MicroRNA-582-3p (miR-582-3p) targets protein tyrosine phosphatase receptor type C-associated protein (PTPRCAP) and modulates Wnt/β-catenin signaling in lung ade...
Benefit-risk evaluation of Fuzheng Yiliu Decoction combined with chemotherapy for treating non-small cell lung cancer using multicriteria decision analysis [0.03%]
基于多准则决策分析的复方益气留淤汤联合化疗治疗非小细胞肺癌的疗效及安全性评估研究
Dongjing Ma,Yingying Yang,Shenwen He et al.
Dongjing Ma et al.
Introduction: This study uses multi-criteria decision analysis (MCDA) to evaluate the benefits and risks of combining Fuzheng Yiliu Decoction with chemotherapy in treating non-small cell lung cancer (NSCLC). The aim is to...